Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)-Reference-Cited by-同舟云学术

Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)

Published:2016-07-25 Issue:16 Volume:76 Page:1519-1527
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Cathomas Richard¹,Crabb Simon J.²,Mark Michael¹,Winterhalder Ralph³,Rothermundt Christian⁴,Elliott Tony⁵,von Burg Philippe⁶,Kenner Heike⁷,Hayoz Stefanie⁷,Vilei Simona Berardi⁷,Rauch Daniel⁸,Roggero Enrico⁹,Mohaupt Markus G.¹⁰,Bernhard Jürg¹¹,Manetsch Gabriela¹,Gillessen Silke⁴,

Affiliation:

1. Oncology/Hematology; Kantonsspital Graubünden; Chur Switzerland

2. Cancer Sciences Unit; University of Southampton; Southampton United Kingdom

3. Department of Oncology Kantonsspital Luzern; Luzern Switzerland

4. Department of Oncology/Hematology; Kantonsspital St. Gallen; St. Gallen Switzerland

5. Department of Oncology; The Christie Clinic; Manchester United Kingdom

6. Department of Oncology; Kantonsspital Aargau; Aarau Switzerland

7. SAKK Coordinating Center; Bern Switzerland

8. Oncology; Hospital Simmental; Thun Switzerland

9. Department of Oncology; Bellinzona IOSI; Bellinzona Switzerland

10. Department of Nephrology; Hypertension and Clinical Pharmacology; University of Bern; Bern Switzerland

11. International Breast Cancer Study Group Coordinating Center Bern and University Hospital; Inselspital Bern Switzerland